Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Alfred Witjes

Showing results (21-30 of 378) with videos related to

Pageof 38
Sort By:
European Urology|August 30, 2008
Editorial comment on: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomyJ Alfred Witjes
Urologic Oncology|May 6, 2009
Management of the first recurrence of T1G3 bladder cancer: does intravesical chemotherapy deserve a chance?J Alfred Witjes
European Urology|August 8, 2015
The Final Answer to the Question of Whether We Should Use a Single Postoperative Instillation of Chemotherapy After Resection of pTa and pT1 Bladder TumorsJ Alfred Witjes
Current Opinion in Urology|August 5, 2011
Perioperative management of nonmuscle-invasive bladder cancerJohannes Falke, J Alfred Witjes
Current Opinion in Urology|August 15, 2006
Intravesical gemcitabine: an update of clinical resultsKees Hendricksen, J Alfred Witjes
Nature Clinical Practice. Urology|October 9, 2007
The role of hexaminolevulinate fluorescence cystoscopy in bladder cancerJ Alfred Witjes, Jude Douglass
Expert Review of Anticancer Therapy|July 24, 2004
Advances in the management of testicular cancerCathy Balk, J Alfred Witjes
Nature Reviews. Urology|January 14, 2011
Contemporary management of low-risk bladder cancerJohannes Falke, J Alfred Witjes
European Urology|August 28, 2007
Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term resultsJ Alfred Witjes, Kees Hendricksen
Current Opinion in Urology|September 1, 2007
Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancerKees Hendricksen, J Alfred Witjes
Pageof 38

Showing results (21-30 of 378) with videos related to

Sort By:
Pageof 38
European Urology|August 30, 2008
Editorial comment on: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomyJ Alfred Witjes
Urologic Oncology|May 6, 2009
Management of the first recurrence of T1G3 bladder cancer: does intravesical chemotherapy deserve a chance?J Alfred Witjes
European Urology|August 8, 2015
The Final Answer to the Question of Whether We Should Use a Single Postoperative Instillation of Chemotherapy After Resection of pTa and pT1 Bladder TumorsJ Alfred Witjes
Current Opinion in Urology|August 5, 2011
Perioperative management of nonmuscle-invasive bladder cancerJohannes Falke, J Alfred Witjes
Current Opinion in Urology|August 15, 2006
Intravesical gemcitabine: an update of clinical resultsKees Hendricksen, J Alfred Witjes
Nature Clinical Practice. Urology|October 9, 2007
The role of hexaminolevulinate fluorescence cystoscopy in bladder cancerJ Alfred Witjes, Jude Douglass
Expert Review of Anticancer Therapy|July 24, 2004
Advances in the management of testicular cancerCathy Balk, J Alfred Witjes
Nature Reviews. Urology|January 14, 2011
Contemporary management of low-risk bladder cancerJohannes Falke, J Alfred Witjes
European Urology|August 28, 2007
Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term resultsJ Alfred Witjes, Kees Hendricksen
Current Opinion in Urology|September 1, 2007
Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancerKees Hendricksen, J Alfred Witjes
Pageof 38